213 related articles for article (PubMed ID: 31707181)
1. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.
Sharma A; Kalyan Mohanti B; Pal Chaudhary S; Sreenivas V; Kumar Sahoo R; Kumar Shukla N; Thulkar S; Pal S; Deo SV; Pathy S; Ranjan Dash N; Kumar S; Bhatnagar S; Kumar R; Mishra S; Sahni P; Iyer VK; Raina V
Eur J Cancer; 2019 Dec; 123():162-170. PubMed ID: 31707181
[TBL] [Abstract][Full Text] [Related]
2. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.
Sharma A; Dwary AD; Mohanti BK; Deo SV; Pal S; Sreenivas V; Raina V; Shukla NK; Thulkar S; Garg P; Chaudhary SP
J Clin Oncol; 2010 Oct; 28(30):4581-6. PubMed ID: 20855823
[TBL] [Abstract][Full Text] [Related]
3. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Phelip JM; Desrame J; Edeline J; Barbier E; Terrebonne E; Michel P; Perrier H; Dahan L; Bourgeois V; Akouz FK; Soularue E; Ly VL; Molin Y; Lecomte T; Ghiringhelli F; Coriat R; Louafi S; Neuzillet C; Manfredi S; Malka D;
J Clin Oncol; 2022 Jan; 40(3):262-271. PubMed ID: 34662180
[TBL] [Abstract][Full Text] [Related]
4. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer.
Hirooka Y; Ishikawa T; Kawashima H; Ohno E; Nonogaki K; Kanamori A; Hirai T; Uchida H; Shirai O; Ishikawa H; Goto H
Cancer Chemother Pharmacol; 2017 Jul; 80(1):119-125. PubMed ID: 28536803
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Bridgewater J; Lopes A; Beare S; Duggan M; Lee D; Ricamara M; McEntee D; Sukumaran A; Wasan H; Valle JW
BMC Cancer; 2016 Feb; 16():153. PubMed ID: 26912134
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.
Ramaswamy A; Ostwal V; Pinninti R; Kannan S; Bhargava P; Nashikkar C; Mirani J; Banavali S
J Hepatobiliary Pancreat Sci; 2017 May; 24(5):262-267. PubMed ID: 28196310
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline
O'Reilly EM; Lee JW; Zalupski M; Capanu M; Park J; Golan T; Tahover E; Lowery MA; Chou JF; Sahai V; Brenner R; Kindler HL; Yu KH; Zervoudakis A; Vemuri S; Stadler ZK; Do RKG; Dhani N; Chen AP; Kelsen DP
J Clin Oncol; 2020 May; 38(13):1378-1388. PubMed ID: 31976786
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.
Sharma A; Mohanti B; Raina V; Shukla N; Pal S; Dwary A; Deo S; Sahni P; Garg P; Thulkar S; DattaGupta S; Rath G
Cancer Chemother Pharmacol; 2010 Feb; 65(3):497-502. PubMed ID: 19575200
[TBL] [Abstract][Full Text] [Related]
16. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.
You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
BMC Cancer; 2019 Jan; 19(1):10. PubMed ID: 30611225
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
19. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS
Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
Malik IA; Aziz Z; Zaidi SH; Sethuraman G
Am J Clin Oncol; 2003 Apr; 26(2):174-7. PubMed ID: 12714891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]